Healy M L, Dawson S J, Murray R M L, Zalcberg J, Jefford M
Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Intern Med J. 2007 Jun;37(6):406-9. doi: 10.1111/j.1445-5994.2007.01371.x.
Insulinomas are the most common hormone-producing pancreatic neuroendocrine tumours (NETs), and patients usually present with symptoms secondary to hypoglycaemia. Octreotide has been widely used in the symptomatic treatment of patients with pancreatic NETs, including insulinomas. We describe a case of a patient with a metastatic NET, subsequently identified as a malignant insulinoma, who developed severe hypoglycaemia after treatment with long-acting octreotide.
胰岛素瘤是最常见的产生激素的胰腺神经内分泌肿瘤（NETs），患者通常表现出继发于低血糖的症状。奥曲肽已广泛用于胰腺NETs患者的对症治疗，包括胰岛素瘤。我们描述了一例转移性NET患者的病例，该患者随后被确诊为恶性胰岛素瘤，在接受长效奥曲肽治疗后出现了严重低血糖。
